Alcohol consumption is considered a major risk factor for disease and mortality worldwide. In the absence of effective treatments in alcohol use disorders, it is important to find new biological targets that could modulate alcohol consumption. We tested the role of the N-terminal galanin fragment (1-15) ] in voluntary ethanol consumption in rats using the two-bottle choice paradigm as well as compare the effects of GAL (1-15) with the whole molecule of GAL. We describe for the first time that GAL(1-15), via central mechanisms, induces a strong reduction in preference and ethanol consumption in rats. These effects were significantly different than GAL. GAL receptor (GALR) 2 was involved in these effects, because the specific GALR2 antagonist M871 blocked GAL(1-15) mediated actions in preference and ethanol intake. Importantly, the mechanism of this action involves changes in GALR expression and also in immediate-early gene C-Fos and receptors-internalization-related gene Rab5 in the striatum. The relevance of the striatum as a target for GAL(1-15) was supported by the effect of GAL(1-15) on the locomotor activity of rats after ethanol administration. These results may give the basis for the development of novel therapeutics strategies using GAL(1-15) analogues for the treatment of alcohol use disorders in humans.
INTRODUCTION
Alcohol consumption is considered a major risk factor for disease and mortality worldwide according to the World Health Organization (2014) . Current therapies in alcohol use disorders (AUD) have limited efficacy, produce several adverse effects and present high rates of relapse. In the absence of effective treatments, it is therefore of great importance to find new biological targets that could modulate alcohol consumption. Numerous neurotransmitters have been implicated in AUD including gamma-aminobutyric acid, glutamate, dopamine, noradrenaline, serotonin and several endogenous neuropeptides (Schneider et al. 2007; Marcinkiewcz, Lowery-Gionta & Kash 2016) .
Galanin (GAL) is a neuropeptide (Tatemoto et al. 1983) widely distributed in neurons within the central nervous system (Jacobowitz, Kresse & Skofitsch 2004 ).
Three GAL receptor (GALR1-3) subtypes with high affinities for GAL have been cloned (Branchek et al. 2000; Mitsukawa, Lu & Bartfai 2008) . GALR1 and GALR3 mainly activate inhibitory G proteins Gi/Go, while GALR2 mainly couples to Gq/G11 to mediate excitatory signalling (Branchek et al. 2000) .
GAL participates in a number of central functions modulating neuroendocrine levels, pain control, cardiovascular functions, food intake and mood disorders (Mitsukawa et al. 2008; Diaz-Cabiale et al. 2010; Lang et al. 2015) . GAL and their receptors are also involved in drug abuse and addiction (Picciotto 2008) , including alcohol intake and alcoholism (Lewis et al. 2004; Lewis et al. 2005) . Microinjection of GAL into the third ventricle increased ethanol consumption in Sprague-Dawley rats in two-bottle choice test from a 7 percent ethanol solution over water, and this increase was completely reversed with the GAL receptor antagonist M40 (Lewis et al. 2004) . These effects of GAL over ethanol consumption were also found with microinjections of GAL directly into the paraventricular nucleus (PVN) of the hypothalamus (Rada et al. 2004) . Moreover, mice overexpressing GAL show an increase in preference and ethanol intake in comparison with their wild-type peers (Karatayev, Baylan & Leibowitz 2009 ), while GAL knockout mice drink less ethanol and decrease the preference for it (Karatayev et al. 2010) . Not only the PVN but also the reward circuitry seems to be involved in the effects of GAL promoting alcohol drinking. The injection of GAL in the PVN increases the dopamine release in the nucleus accumbens (Rada, Mark & Hoebel 1998) , and this effect would be consistent with the ability of GAL to increase the rewarding effects of alcohol (Picciotto et al. 2010) .
In addition to GAL, also the N-terminal fragments like GAL(1-15) are active in the central nervous system (Hedlund & Fuxe 1996; Diaz-Cabiale et al. 2005; Diaz-Cabiale et al. 2010; Millon et al. 2015; Millon et al. 2016; Flores-Burgess et al. 2017; Millon et al. 2017) . Both GAL and GAL(1-15) molecules have specific roles in cardiovascular regulation and interact differently with other neuropeptides (Diaz-Cabiale et al. 2005) . Recently, we have described that GAL(1-15) induces a strong depression-related and anxiogenic-like effects in rats, and these effects were significantly stronger than the ones induced by GAL. The GALR1/GALR2 heteroreceptor complexes in the dorsal hippocampus and especially in the dorsal raphe, areas rich in GAL(1-15) binding sites (Hedlund, Yanaihara & Fuxe 1992) , were involved in these effects (Millon et al. 2015) . The presence of specific binding sites for GAL (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) in the dorsal hippocampus, neocortex and striatum (Hedlund et al. 1992) , which is part of mesolimbic dopamine system (Koob 1992) , suggests a role of GAL(1-15) in the circuits related to the rewarding and motivational effects of drugs of abuse.
The purpose of the current study was to assess the role of intracerebroventricular (i.c.v.) GAL(1-15) in voluntary ethanol consumption in rats using the twobottle choice paradigm as well as compare the effects of GAL(1-15) with the GAL. Moreover, the involvement of GALR2 in GAL(1-15)-mediated effects in this test was analysed with the selective GALR2 antagonist M871. In order to investigate whether the effect of GAL(1-15) in voluntary ethanol consumption was associated with the reward circuit, we have studied in the striatum the effect of GAL(1-15) in the expression of the immediateearly gene C-Fos, the receptors-internalization related gene Rab5 and the GALR1 and GALR2. We therefore investigated the effects of GAL(1-15) treatment on the locomotor activity induced by alcohol.
MATERIAL AND METHODS

Animals
Male Sprague-Dawley rats (body weight 225-250 g, age 8 weeks) were obtained from Criffa and maintained in a humidity-controlled and temperature-controlled (20-22°C) room. The rats in the two-bottle choice paradigm were during the entire protocol maintained on a 12-hour reversed light/dark cycle (lights off at 10 am) whereas the other rats kept on 12-hour light/dark cycle. The animals had free access to food pellets and tap water. All animal experimentation was conducted in accordance with the University of Málaga Guidelines for the Care and Use of Laboratory Animals.
Intracerebroventricular injections
This protocol has been used previously (Diaz-Cabiale et al. 2011; Millon et al. 2015) . Briefly, the rats were anaesthetised intraperitoneally with Equitesin (21.3 g choral hydrate, 10.6 g magnesium sulphate and 4.8 g phenobarbitone dissolved in 500 ml distillated water containing 9.5 percent ethanol and propylene glycol; 3.3 ml/kg body weight) and stereotaxically implanted with a unilateral chronic 22-gauge stainless-steel guide cannula into the right lateral cerebral ventricle using the following coordinates: 1.4 mm lateral and 1 mm posterior to bregma and 3.6 mm below the surface of the skull (Paxinos 1986 ). After surgery, animals were individually housed and allowed a recovery period of 7 days. The injections in the lateral ventricle were performed using a 26-gauge stain less-steel injection cannula connected via a PE-10 tubing to a Hamilton syringe. The total volume was 5 μl per injection, and the infusion time was 1 minute.
Solutions were prepared freshly, and the peptides were dissolved in artificial cerebrospinal fluid (composition is 120 nM NaCl, 20 nM NaH2CO3, 2 nM KCl, 0.5 nM KH2PO4, 1.2 nM CaCl2, 1.8 nM MgCl2, 0.5 nM Na2SO4 and 5.8 nM D-glucose, pH 7.4). GAL was obtained from NeoMPS, Strasbourg, France; GAL(1-15) and the GALR2 receptor antagonist M871 were obtained from Tocris Bioscience, Bristol, UK.
Two-bottle choice test for voluntary ethanol consumption and preference
The two-bottle choice test was used to determine the voluntary ethanol consumption of rats as described previously (Castilla-Ortega et al. 2016) . Briefly, after 7 days of water consumption (both bottles), a choice between water and increasing ethanol concentration [3, 6 and 10 percent (v/v) ] was offered for 7 days each. A choice between 10 percent (v/v) ethanol and water was offered for several days until reaching a stable baseline. Water and ethanol consumption were recorded daily. The bottles positions were changed every day to avoid position preferences. Water intake (g/kg), ethanol intake (g/kg) and preference [ethanol consumption/total fluid (water plus ethanol) consumption ×100 were calculated for each animal. Throughout the experiment, evaporation/spillage estimates were calculated using an empty cage with two bottles, one containing water and the other containing the appropriate ethanol solution.
In the experiments, a choice between ethanol (10 percent) and water was offered.
Three sets of experiments were conducted in the twobottle choice paradigm. In the first set of experiments, a dose-response curve of GAL(1-15) was performed. For this, groups of rats received i.c.v. GAL(1-15) 1, 3 nmol or vehicle 2, 14 and 24 hours before the measures. In the second set of experiments, the effects in two-bottle choice test of GAL and GAL(1-15) were compared. For this, groups of rats received i.c.v. GAL 3 nmol, GAL(1-15) 3 nmol or vehicle 2, 14 and 24 hours before the test. In the last set of experiments, the role of the GALR2 was studied; for this, groups of rats received i.c.v. GAL(1-15) 3 nmol combined with GALR2 antagonist M871 3 nmol 2 hours before the measures.
The general schema of the experimental design is shown in figure 1.
mRNA expression of galanin receptors, C-Fos and Rab5 genes in the striatum in voluntary ethanol consumption Groups of rats from the two-bottle choice paradigm were killed by decapitation 2 hours after a single i.c.v. administration of GAL(1-15) 3 nmol or vehicle. The rats had free access to ethanol and water until the moment of sacrifice. The corpus striatum was manually dissected, including both the dorsal and ventral areas from 2.2 mm anterior to bregma to 1.8 mm to bregma (Paxinos 1986 ) and frozen on solid CO 2 until mRNA expression analysis.
RNA isolation and quantitative real-time polymerase chain reaction analysis
The procedure to perform RNA isolation and real-time polymerase chain reaction (RT-PCR) was described previously (Millon et al. 2015) . Total RNA was isolated from the striatum using RNeasy Lipid Tissue Kit (Qiagen, Hilden, Germany). cDNA was obtained using a Reverse Transcriptase Core Kit (Eurogentec, Seraing, Belgium). These steps were performed according to the manufacturer's instructions.
All PCR were conducted in triplicate using Power SYBR Green PCR Master Mix (Applied Biosystems, Foster City, USA) in 7500 RT-PCR system (Applied Biosystems, Foster City, USA). The primers sequences used in this study are GAPDH-Forward: 5 0 -GCTCTCTGCTCCTCCCTGTTC; 
Alcohol dehydrogenase assay
The activity of hepatic cytosolic alcohol dehydrogenase (ADH) in the rats from the two-bottle choice test was analysed. ADH activity has a good correlation with ethanol elimination rates in vivo (Lumeng, Bosron & Li 1979) , and chronic ethanol administration causes an increase in ADH activity (Buris et al. 1985) . The livers were removed 2 hours after i.c.v. injections and frozen in solid CO 2 until use. Determination of ADH activity was perform in homegenated of liver tissue in TrisHCl solution (10 mM pH 8,8 0.5 mM dithiothreitol) centrifuged at 12.000 g during 10 min. ADH activity was evaluated using a microassay adapted to Cobas Mira according to Shephard and colleges (Shephard, Penberthy & Berry 1987) . Briefly, 300 μl of NAD solution (2.9 mM in 0.1 M Glycine/NaOH pH 10) was added to 30 μl of sample. The first optical reading was recorded before the addition of 20 μl of Figure 1 Experimental design of voluntary ethanol intake. i.c.v., intracerebroventricular 17 mM ethanol, and then the rate of change in absorption of the NADH chromogen is monitored at 340 nm over time on the Cobas Mira at 37°C. One activity unit was defined as the reduction of 1 mol NAD to NADH/min at 37°C.
Locomotor activity experiments
In this experiment, the effects of GAL(1-15) (3 nmol) on ethanol-reduced locomotion [1.75 g/kg; intraperitoneal (i.p.)] (Vallof et al. 2016) were investigated. Locomotor activity was registered in the rat open field (100 × 100 × 50 cm) where animals were individually placed and allowed to freely explore. Their behaviour was recorded over 30-minute period by ceilingmounted video camera, and locomotor activity was analysed using the video-tracking software EthovisionXT. After each trial, all surfaces were cleaned with a paper towel and 70 percent ethanol solution. For the locomotor activity, the total distance travelled (cm) and mean speed (cm/s) were recorded. Groups of rats were administrated via i.c.v. with GAL(1-15) or vehicle 20 minutes before the test and the i.p. ethanol (1.75 g/kg) or saline administration was 5 minutes prior the test.
Expression of mRNA of GALR1 and GALR2 after acute administration of ethanol Groups of naïve rats were injected i.p. with ethanol 4 g/kg (50 percent v/v 10 ml/kg) (Bilbao et al. 2016) , dissolved in sterile saline 0.9 percent (w/v), and 0, 2 and 4 hours after injection, the brains were collected after a rapid decapitation. The corpus striatum was manually dissected, including both the dorsal and ventral areas from 2.2 mm anterior to bregma to 1.8 mm posterior to bregma (Paxinos 1986 ) and frozen immediately on solid CO 2 until use. The procedure to perform RNA isolation and RT-PCR was described previously.
Statistical analysis
Data are presented as the means ± standard error of the mean, and sample numbers (n) are indicated in figure legends. All data were analysed using GraphPad PRISM 4.0 (GraphPad Software). For comparing two experimental conditions, Student's unpaired t-test statistical analyses were performed. Otherwise, one-way analyses of variance (ANOVAs) or two-way ANOVAs followed by Fisher's least significant difference (LSD) comparison post-tests were performed. Differences were considered significant at P < 0.05 (*P < 0.05, ** P < 0.01, *** P < 0.001).
RESULTS
Liver alcohol dehydrogenase activity in voluntary ethanol consumption
Voluntary ethanol intake through two-bottle choice test protocol induced a significant increase in the ADH activity compared with baseline group (t 11 = 3.281 P < 0.01), confirming the validity of our model (Table 1) .
GAL(1-15) induced a decrease of ethanol intake and alcohol preference in the two-bottle choice paradigm GAL(1-15) at 3 nmol significantly decreased the ethanol intake at 2 hours (one-way ANOVA, F 2,30 = 3.54, P < 0.05, Fisher's LSD post hoc test: P < 0.05; Fig. 2a ), 14 hours (one-way ANOVA, F 2,30 = 3.44, P < 0.05, Fisher's LSD post hoc test: P < 0.05; Fig. 2b ) and 24 hours (one-way ANOVA, F 2,29 = 3.59 P < 0.05, Fisher's LSD post hoc test: P < 0.05; Fig. 2c ) after its administration. GAL(1-15) at the dose of 1 nmol lacked effect on ethanol intake in all the time-points analysed.
Moreover, 2 hours after i.c.v. GAL(1-15) 3 nmol a significantly decreased by 90 percent in preference was observed (one-way ANOVA, F 2,31 = 3.46 P < 0.05, Fisher's LSD post hoc test: P < 0.05; Fig. 2g ). This effect was maintained 24 hours (one-way ANOVA, F 2,31 = 3.57 P < 0.05, Fisher's LSD post hoc test: P < 0.05; Fig. 2i ). The dose of GAL(1-15) 1 nmol lacks again of effects in preference.
In the water (Fig. 2d ,e,f) and food intake (Fig. 2j ,k,l), no differences were found at any time-point after GAL(1-15) i.c.v. administration at any dose.
These results indicate that GAL(1-15) evokes a strong decrease in voluntary ethanol intake and preference in rats.
Comparison between GAL and GAL(1-15) in the two-bottle choice paradigm
In the ethanol intake, the overall one-way ANOVA revealed a significant difference between the N-terminal Table 1 Liver ADH activity of animals of two-bottle choice paradigm.
ADH Activity
Treatment
Baseline Veh/EtOH ADH (Ui/g protein) 251.4 ± 14.8 313.1 ± 10.6** Effects of voluntary ethanol intake in animals of two-bottle choice test over the liver ADH activity. Cerebrospinal fluid-injected rats were used as the vehicle group, and naïve rats were used as baseline group. Data are mean ± standard error of the mean (n = 6-7 animals per group). ADH = alcohol dehydrogenase. **P < 0.01 versus baseline group according to Student's t-test.
fragment GAL(1-15) and GAL at 2, 14 and 24 hours after treatments. Two hours after the injection, GAL(1-15) significantly reduced the ethanol intake compared with GAL (one-way ANOVA, F 2,31 = 4.208 P < 0.05, Fisher's LSD post hoc test: P < 0.01; Fig. 3a) . The same pattern of response was observed at the others times, GAL(1-15) significantly decreased the ethanol intake versus GAL groups 14 (one-way ANOVA, F 2,30 = 3.97 P < 0.05, Fisher's LSD post hoc test: P < 0.05; Fig. 3b ) and 24 hours (one-way ANOVA, F 2,30 = 2.53 P < 0.05, Fisher's LSD post hoc test: P < 0.05; Fig. 3c ) after i.c.v. injection. On the preference, the difference between GAL and GAL(1-15) was observed again. GAL(1-15) decreased the preference compared with GAL 2 hours after its administration (one-way ANOVA, F 2,30 = 3.55 P < 0.05, Fisher's LSD post hoc test: P < 0.05; Fig. 3g ), effect that was maintained 24 hours later (one-way ANOVA, F 2,32 = 3.43 P < 0.05, Fisher's LSD post hoc test: P < 0.05; Fig. 3i ).
GAL lacks effect on the ethanol intake and preference compared with the vehicle at any time-point (Fig. 3) .
No differences were found between GAL and the fragment GAL(1-15) in water intake (Fig. 3d ,e,f) and food intake (Fig. 3j,k,l) .
GALR2 antagonist M871 blocked GAL(1-15)-mediated effects in the two-bottle choice paradigm
In the two-bottle choice test, GALR2 antagonist M871 significantly blocked the decreased in the ethanol intake in the two-bottle choice paradigm with 10 percent ethanol (EtOH) concentration in rats. GAL1-15 (at 1 or 3 nmol/rat) (n = 7-9 animals per group) was administrated intracerebroventricular 2, 14 and 24 hours before the measures. Cerebrospinal fluid-injected rats were used as the vehicle group (n = 15-18 animals). Vertical bars represent mean ± standard error of the mean of EtOH intake (g/kg; a, b, c), water intake (g/kg; d, e, f), preference EtOH (percent; g, h, i) and food intake (g; j, k, l) during the different periods. (a) * P < 0.05 versus rest of the groups (rest of graphs) * P < 0.05 versus vehicle group according to one-way ANOVA followed by Fisher's least significant difference test (one-way ANOVA, F 2,34 = 3.72, P < 0.05, Fisher's LSD post hoc test: P < 0.05; Fig. 4a ) induced by GAL(1-15) 2 hours after its administration. In the preference, the same type of change was observed. Thus, GALR2 participates in GAL(1-15)-mediated effect, because the GALR2 antagonist M871 significantly blocked the decreased on preference induced by GAL(1-15) (one-way ANOVA, F 2,32 = 3.39, P < 0.05, Fisher's LSD post hoc test: P < 0.05; Fig. 4c ).
The GALR2 antagonist M871 alone at the dose of 3 nmol lacked effects on ethanol intake (0.13 ± 0.06 g/kg) and preference (12.65 ± 8.23 percent).
Neither water (Fig. 4b ) nor food intake ( Fig. 4d) were modified by M871 (water intake: 8.26 ± 2.00 g/kg; food intake: 6.67 ± 0.95 g) or GAL(1-15) + M871 2 hours after injection.
GAL(1-15) effects mRNA expression of galanin receptors, C-Fos and Rab5 genes in the striatum in voluntary ethanol consumption
As shown in figure 5, GAL(1-15) at dose of 3 nmol produced a significant increase in the mRNA levels of C-Fos (t 8 = 5.488 P < 0.001; Fig. 5a ) and Rab5 (t 6 = 4.148 P < 0.01; Fig. 5b ) in the two-bottle choice test 2 hours after its administration.
The administration of GAL(1-15) also modified the GALR1 and GALR2 receptors expression in striatum, Figure 3 Effect of administration of galanin (GAL) and galanin (1-15) (GAL1-15) in the two-bottle choice paradigm with 10 percent ethanol (EtOH) concentration in rats. GAL (3 nmol/rat) and GAL1-15 (3 nmol/rat; n = 7-13 animals per group) were administrated intracerebroventricular 2, 14 and 24 hours before the measures. Cerebrospinal fluid-injected rats were used as the vehicle group (n = 10-15 animals). Vertical bars represent mean ± standard error of the mean of EtOH intake (g/kg; a, b, c), water intake (g/kg; d, e, f), preference EtOH (percent; g, h, i) and food intake (g; j, k, l) during the different periods. (a) * P < 0.05 versus vehicle and ** P < 0.01 versus GAL1-15 3 nmol group (rest of graphs) * P < 0.05 versus rest of the groups according to one-way ANOVA followed by Fisher's least significant difference test Figure 4 Effects of co-administration of GALR2 receptor antagonist M871 (3 nmol/rat) and galanin(1-15) (GAL1-15) (n = 7-9 animals per group) in the two-bottle choice paradigm with 10 percent ethanol (EtOH) concentration in rats. Treatments were injected intracerebroventricular 2 hours before the measures. Cerebrospinal fluid-injected rats were used as the vehicle group (n = 18-20 animals). Vertical bars represent mean ± standard error of the mean of (a) EtOH intake (g/kg), (b) water intake (g/kg), (c) preference EtOH (percent) and (d) food intake (g) during the different periods. * P < 0.05 versus rest of the groups according to one-way ANOVA followed by Fisher's least significant difference test Figure 5 Effects of galanin(1-15) (GAL1-15) in the striatum mRNA expression of (a) C-Fos, (b) Rab5, (c) GALR1 and (d) GALR2 in the two-bottle choice paradigm exposed rats. GAL1-15 was injected intracerebroventricular 2 hours before the measures. Cerebrospinal fluid-injected rats were used as the vehicle group. Vertical bars represent mean ± standard error of the mean (n = 5-6 animals per group). * P < 0.05; ** P < 0.01; *** P < 0.001 versus Veh/EtOH group according to Student's t-test producing a significant decreased of GALR1 mRNA levels (t 10 = 2.341 P < 0.05; Fig. 5c ) and a slight reduction in GALR2 expression (t 10 = 1.360 P = 0.101; Fig. 5d ), suggesting the involvement of both receptors in the effects of GAL(1-15).
Effects of GAL(1-15) on ethanol-reduced locomotion As previously described, the i.p. administration of ethanol 1.75 g/kg reduced the distance travelled (one-way ANOVA, F 1,25 = 62.2, P < 0.001) and the mean speed (one-way ANOVA, F 1,25 = 62.2 P < 0.001) 5 minutes after its administration (Fig. 6 ).
The effect of GAL(1-15) 3 nmol on locomotion (distance travelled and mean speed) was dependent on i. p. ethanol (distance travelled: two-way ANOVA for alcohol/i.c.v.-treatment interaction F 1,25 = 7.19, P < 0.01; mean speed two-way ANOVA for alcohol/i.c. v.-treatment interaction F 1,25 = 7.19, P < 0.01; Fig. 6 ). Thus, in rats following i.p. administration of ethanol, GAL(1-15) decreased the distance travelled (Fisher's LSD post hoc test: P < 0.001; Fig. 6a) , whereas no such effects were observed in rats with systemic administration of saline (Fisher's LSD post hoc test: P = 0.71; Fig. 6a ). Similar to the distance travelled, GAL(1-15) decreased the mean speed only in the rats systemically treated with ethanol (Fisher's LSD post hoc test: P < 0.001; Fig. 6b ).
GALR1 and GALR2 expression in the striatum after the acute administration of ethanol To determine whether ethanol influenced GALR1 and GALR2 expression in the striatum, we evaluated the effects of the acute ethanol administration on mRNA GALR1 and GALR2 levels in the striatum at 2 and 4 hours.
As shown in figure 7 , a single ethanol injection (4 g/kg i.p.) lacked effect in the GALR1 expression in the striatum 2 and 4 hours after administration (one-way ANOVA, F 2,14 = 1.19 P = 0.24).
No effects were observed also in the GALR2 mRNA levels in any of the time-points (one-way ANOVA, F 2,14 = 1.15 P = 0.34).
DISCUSSION
In the current study, we described for the first time that GAL(1-15), via central mechanisms, induces a strong reduction in preference and ethanol consumption in rats. These effects were significantly different than GAL, showing a differential role of GAL compared with GAL(1-15) in alcohol consumption behaviour. GALR2 was involved in these effects, because the specific GALR2 antagonist M871 blocked GAL(1-15) mediated actions in preference and ethanol intake. Importantly, the mechanism of this action involves changes in GAL receptors expression and also in immediate-early gene C-Fos and receptorsinternalization-related gene Rab5 in striatum, area rich in GAL-fragment binding sites (Hedlund et al. 1992) and critical for the rewarding and motivational effects of drugs of abuse (Koob 1992) . The relevance of the striatum as a target for GAL(1-15) was also supported by the effect of GAL(1-15) on the locomotor activity of rats after ethanol administration.
GAL(1-15) at the dose of 3 nmol induced a strong reduction in preference and ethanol consumption in the two-bottle choice test at 2 hours, effect that was maintained at 24 hours. Given that this alcohol twobottle-choice drinking paradigm induces voluntary intake of high amounts of alcohol (Simms et al. 2008 ), the present data may suggest that GAL(1-15) could be used as a pharmacological agent to treat AUD in humans.
Although emotional states as anxiety are relevant variables to modulate alcohol-taking behaviour, increasing alcohol consumption and preference (Chappell et al. 2013) , and GAL(1-15) increases anxiety-like and depressive-like behaviours in rats (Millon et al. 2015; Millon et al. 2017) , the fact that GAL(1-15) induced a Figure 6 Effects of galanin (1-15) (GAL1-15) in ethanol-induced locomotors modification in rats. GAL1-15 (3 nmol; intracerebroventricular) was injected 20 minutes before the test, and acute injection of ethanol (1.75 g/kg; intraperitoneal) was administrated 5 minutes before the test. Data represents mean ± standard error of the mean (n = 6-8 animals per groups) of (a) total distance travelled and (b) mean speed in open field during the 5-minute test period.
*** P < 0.001 according to two-way ANOVA followed by Fisher's least significant difference test reduction in alcohol intake and preference suggests that the mechanism involved is independent of the effect of GAL(1-15) in the emotional states. In addition, a tentative explanation for the reduced alcohol intake induced by central GAL(1-15) administration is that GAL(1-15) by itself may induce aversion rather than attenuate the rewarding properties of alcohol. However, the selected doses of GAL(1-15) lack effect on water and food intake suggesting that the reduced alcohol intake is not driven by aversion to alcohol.
Because GAL(1-15) did not modify the food intake in rats that had been chronically consuming ethanol, it can also be suggested that in our model, the rats were not consuming ethanol just for its calories (Lewis et al. 2004) .
Furthermore, the effects of GAL(1-15) in the two-bottle choice test were significantly different than the corresponding effects induced by GAL. In our model, GAL 3 nmol lacked effect with respect to vehicle group in all the parameters studied. In previous studies, GAL microinjected into the third ventricle increased the 7 percent ethanol intake in the two-bottle choice test (Lewis et al. 2004) , and this increase was stronger during the light phase, when the animals are inactive and normally drink very little (Lewis et al. 2004) . The different results found in the present work could be explained in the differences of the percentage of ethanol and the light-dark cycle used, because we used the choice between 10 percent ethanol versus water, and the percentage of ethanol solution could affect the result of the test (Leeman et al. 2010; Tarragon et al. 2012) . Moreover, we performed the measures in the dark period, when the rats are more active, while the ethanol intake produced by GAL was stronger in the light period (Lewis et al. 2004) .
However, because GAL(1-15) reduced the preference and ethanol consumption, opposite effect found by GAL by other authors, our results validate and extend the view of a specific role of GAL(1-15) in ethanol intake.
We have previously described a different action of GAL and GAL(1-15) in behaviour functions . GAL(1-15) induces depression-related and anxiogenic-like effects in rats, and these effects were significantly stronger than the one induced by GAL (Millon et al. 2015) . GAL(1-15) is also able to enhance the antidepressant effects induced by the 5HT1A agonist 8-OH-DPAT in the forced swimming test, an effect that was again significantly stronger than the one induced by GAL (Millon et al. 2016) . The different action between GAL and GAL(1-15) was observed not only in behavioural functions but also in central cardiovascular regulation (Diaz-Cabiale et al. 2005; Diaz-Cabiale et al. 2010) . Our results in the ethanol intake confirm a unique action of GAL(1-15) in brain communication.
The mechanism that explained the differences between the GAL and GAL(1-15) is that this N-terminal GAL fragment preferring site is the result of formation of GALR1/GALR2 heteromers highly specific for GAL fragments (Fuxe et al. 2008; Fuxe et al. 2012; Millon et al. 2015) . The fact that GALR2 antagonist M871 blocked the reduction in preference and ethanol intake induced by GAL(1-15) confirms that GAL(1-15) acts through heterodimer GALR1/GALR2 to reduce the preference and ethanol consumption.
The GAL receptors involved in alcoholism are not well characterized; however, several studies suggested that GALR3 was involved in alcohol consumption (Belfer et al. 2007; Ash et al. 2011; Ash et al. 2014; Scheller et al. 2017) . Because GALR3 is mainly restricted to the hypothalamus and pituitary (Smith et al. 1998; Waters & Krause 2000) , it has been proposed that these areas are crucial for this effect. Our results demonstrate the importance of GALR1 and GALR2 in the reduction of preference and ethanol intake induced by GAL(1-15) and suggest that the striatum, a key region in the reward effects of drugs (Koob 1992) , is involved in GAL(1-15)-mediated effects. In our voluntary ethanol consumption model, GAL(1-15) induced a significant increase of C-Fos mRNA and Rab5 expression in the striatum suggesting an enhancement of neuronal activation and receptor internalization in this area . Moreover, in these animals, we observed after GAL(1-15) injection a significant reduction of GALR1 expression and a slight decrease in GALR2 Figure 7 Effects of ethanol administration on galanin receptor (GALR)1 and GALR2 expression in the striatum. Effects of acute intraperitoneal administration of EtOH (4 g/kg) on (a) GALR1 and (b) GALR2 mRNA expression in striatum were measured at 0, 2 and 4 hours after injection. Data are mean ± standard error of the mean (n = 4-8 animals per group). No significant differences were found by one-way ANOVA mRNA in the striatum suggesting that both striatal receptors participated in the GAL(1-15)-mediated effects on the voluntary ethanol intake in this nucleus. Interestingly, the evidence that acute ethanol injections in naïve animals lack of effect in GALR1 and GALR2 expression in the striatum indicates that ethanol per se does not influence GALR expression and confirms that the effects at GALR level in our model were induced by GAL (1-15) .
The relevance of the striatum as a target for GAL(1-15) was supported by the ability of GAL(1-15) to enhance the suppression of locomotor activity induced by ethanol. Ethanol suppression of locomotor activity following ethanol i.p. injection is a well-known behavioural effect mainly mediated by the dopaminergic system, involving the striatum. Accordingly, it has been demonstrated that this effect is notably reduced when the dopaminergic system is lesioned using 6-OHDA, producing strong dopamine depletion in the striatum (Breese et al. 1984) . Our results suggest that the potentiation of the hypolocomotion induced by GAL(1-15) in rats treated with alcohol may require the modulation of the dopaminergic system by GAL(1-15), probably involving the striatum because it is a crucial target of the dopaminergic projections.
Although previously, the increase in the ethanol intake of GAL was related directly with several areas within the hypothalamus (Leibowitz et al. 2003; Rada et al. 2004; Schneider et al. 2007) , the current work suggests that GAL(1-15) acts through the striatum, an area that has specifics binding sites for GAL(1-15) (Hedlund et al. 1992) . The involvement of the striatum in GAL(1-15)-mediated action would explain the different action between GAL and GAL(1-15) in ethanol intake.
Further studies are needed to describe the neurochemical pathways involved in the reduction of ethanol consumption by GAL (1-15) ; however, the dopamine should be consider a target neurotransmitter in this effect. Supporting this hypothesis, GAL reduces behavioural response following treatment with several addictive substances such as morphine or amphetamines mainly modulating dopaminergic neurotransmission (Tsuda et al. 1998; Pierce & Kumaresan 2006) , and dopamine transmission plays a crucial role in the motor effects of alcohol in the striatum (Brabant, Guarnieri & Quertemont 2014) .
In conclusion, our results indicate that the N-terminal fragment GAL(1-15) induces a strong reduction in preference and ethanol consumption in rats probably with the involvement of the striatum, a key region in the reward effects of drugs. These results may give the basis for the development of novel therapeutics strategies using GAL(1-15) analogues for the treatment of AUD in humans.
